Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.

The present study aimed to evaluate the side-effects and efficacy of thalidomide in combination with an anthracycline-containing chemotherapy regimen in previously untreated myeloma patients. Thalidomide (400 mg/d) was combined with bolus injections of vincristine and epirubicin and oral dexamethaso...

書誌詳細
主要な著者:	Schütt, P, Ebeling, P, Buttkereit, U, Brandhorst, D, Opalka, B, Hoiczyk, M, Flasshove, M, Hense, J, Bojko, P, Metz, K, Moritz, T, Seeber, S, Nowrousian, MR
フォーマット:	Journal article
言語:	English
出版事項:	2005

類似資料

Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
著者:: Schütt, P, 等
出版事項: (2005)

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
著者:: Schütt, P, 等
出版事項: (2005)

Immune parameters in multiple myeloma patients: influence of treatment and correlation with opportunistic infections.
著者:: Schütt, P, 等
出版事項: (2006)

Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma.
著者:: Nowrousian, MR, 等
出版事項: (2005)

The clinical significance of soluble human leukocyte antigen class-I, ICTP, and RANKL molecules in multiple myeloma patients.
著者:: Schütt, P, 等
出版事項: (2008)

Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients.
著者:: Rebmann, V, 等
出版事項: (2007)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
著者:: Juan M. Cano-Calderón, 等
出版事項: (2025-01-01)

High dose Simvastatin does not reverse resistance to Vincristine, Adriamycin, and Dexamethasone (VAD) in Myeloma
著者:: E. van der Spek, 等
出版事項: (2007-12-01)

P21 EFFECTIVENESS AND SAFETY OF DELAYED BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE (VTD) REGIMEN
著者:: V. Del Fabro, 等
出版事項: (2023-05-01)

Renal pathological changes after successful treatment of LCDD using cyclophosphamide, thalidomide, and dexamethasone
著者:: Di Wang, 等
出版事項: (2021-01-01)

Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India
著者:: Nithin Sashidharan, 等
出版事項: (2015-05-01)

Superiority of the triple combination of bortezomib, cyclophosphamide and dexamethasone versus cyclophosphamide, thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma, eligible for transplantation
著者:: Edvan De Queiroz Crusoe, 等
出版事項: (2020-04-01)

Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
著者:: Yin-Che Wang, 等
出版事項: (2025-12-01)

A Case Report of Leptomeningeal Myelomatosis and Rapid Improvement with Regimen Consisting of Daratumumab, Pomalidomide, Vincristine, Procarbazine, and Dexamethasone
著者:: Jew Win Kuan, 等
出版事項: (2022-01-01)

The efficacy and tolerability of bortezomib, thalidomide, and dexamethasone induction therapy with a thalidomide dose step‐up strategy in patients with newly diagnosed multiple myeloma: A prospective observational study
著者:: Po‐Wei Liao, 等
出版事項: (2024-05-01)

Bortezomib in combination with low-dose oral melphalan, dexamethasone and thalidomide for relapsed elderly patients with multiple myeloma
著者:: Taleb Azarm, 等
出版事項: (2012-01-01)

Altered Regional Brain Glucose Metabolism in Diffuse Large B-Cell Lymphoma Patients Treated With Cyclophosphamide, Epirubicin, Vincristine, and Prednisone: An Fluorodeoxyglucose Positron Emission Tomography Study of 205 Cases
著者:: Yuxiao Hu, 等
出版事項: (2022-06-01)

Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
著者:: Laura Rosiñol, 等
出版事項: (2023-11-01)

Preexposure of MCF-7 breast cancer cell line to dexamethasone alters the cytotoxic effect of paclitaxel but not 5-fluorouracil or epirubicin chemotherapy
著者:: Buxant F, 等
出版事項: (2017-03-01)

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
著者:: Martin Kropff, 等
出版事項: (2012-05-01)

Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible
著者:: Suhailur Rehman, 等
出版事項: (2017-07-01)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
著者:: Karthik Ramasamy, 等
出版事項: (2022-11-01)

Thalidomide in treatment of connective diseases and vasculities
著者:: D. Ribatti, 等
出版事項: (2011-09-01)

Nanoparticle Effect on Interaction of Epirubicin with DNA
著者:: Leyla Karadurmus, 等
出版事項: (2017-11-01)

P1067: PHASE 2 STUDY OF ORAL THALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE FOR RECURRENT/REFRACTORY ADULT LANGERHANS CELL HISTIOCYTOSIS
著者:: J.-N. Wang, 等
出版事項: (2022-06-01)

New therapies for heart failure: is thalidomide the answer?
著者:: Davey, P, 等
出版事項: (2000)

Thalidomide, the story goes on
著者:: Esther Papaseit, 等
出版事項: (2023-06-01)

Treatment of Aphthae with Thalidomide
著者:: Mahmoud Farshchian
出版事項: (1994-03-01)

Thalidomide in dermatology: Revisited
著者:: Iffat Hassan, 等
出版事項: (2015-01-01)

Gammel Testamente ved Det Teologiske Fakultet ved Aarhus Universitet
著者:: Hans J. Lundager Jensen
出版事項: (2009-09-01)

Genoptagelse ved hjælp af proformer ved simultantolkning fra tysk
著者:: Friedel Dubslaff
出版事項: (2017-02-01)

Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study
著者:: Patrice Chevallier, 等
出版事項: (2015-04-01)

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma
著者:: Henk M. Lokhorst, 等
出版事項: (2008-01-01)

Reaksjonene ved promillekjøring
著者:: R. N. Torgersen
出版事項: (1984-05-01)

Straffutmålingsnivået ved voldsforbrytelser
著者:: Georg Fr. Rieber-Mohn
出版事項: (1988-08-01)

Styring ved straff
著者:: Nils Christie
出版事項: (2000-09-01)

Epidemiologi ved korsryggsmerter
著者:: Dag Magnar Soldal
出版事項: (2008-01-01)

Studieplanlægning ved lægeuddannelserne
著者:: Anne Mette Mørcke, 等
出版事項: (2010-03-01)

Gaveøkonomi ved Nasjonalmuseet
著者:: Ane Moe
出版事項: (2016-01-01)

Polyphosphazene-Based Nanocarriers for the Release of Camptothecin and Epirubicin
著者:: Javier Pérez Quiñones, 等
出版事項: (2022-01-01)